After a pharmaceutical study, the European Union has approved Femara, Novartis's new breast cancer drug
(swissinfo.ch)
The Novartis healthcare group in Basel says the European Union has approved its Femara drug for the treatment of advanced breast cancer in post-menopausal women.
Femara also received approval from Britain's Medicine Control Agency for first-line breast cancer treatment under a separate national procedure, the group said.
A Novartis statement on Friday said that approval of the treatment was based on a study which showed that Femara delayed the progression of advanced breast cancer for 9.4 months, compared to six months for tamoxifen, the standard therapy.
"This is exciting news for the thousands of post-menopausal women with advanced breast cancer because Femara presents a more effective option than the gold standard tamoxifen in treating their disease," said Dr Henning Mouridsen, a professor at Copenhagen University Hospital and lead investigator for the drug trial.
The study also showed favourable differences on overall tumour response rates, clinical benefits, and time to treatment failure.
Novartis said adverse reactions to Femara were generally mild to moderate, the most commonly reported being bone pain, hot flushes, back pain, nausea and arthralgia.
Earlier this month, Femara received approval from the United States Food and Drug Administration.
All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.
As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.
